Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Sees Large Decline in Short Interest

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the target of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 7,595 shares, a decrease of 72.6% from the July 15th total of 27,721 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Laboratorios Farmaceuticos Rovi Price Performance

Shares of LABFF remained flat at C$67.17 during trading hours on Friday. Laboratorios Farmaceuticos Rovi has a fifty-two week low of C$65.86 and a fifty-two week high of C$67.17. The company has a 50-day simple moving average of C$65.84 and a 200 day simple moving average of C$65.86.

About Laboratorios Farmaceuticos Rovi

Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.